Hostname: page-component-699b5d5946-pzwhm Total loading time: 0 Render date: 2026-02-28T10:38:48.509Z Has data issue: false hasContentIssue false

Reply to Khosrowshahi

Published online by Cambridge University Press:  26 February 2026

Michael Klompas*
Affiliation:
Department of Population Medicine, Harvard Medical School, Boston, USA Department of Medicine, Brigham and Women’s Hospital, Boston, USA
Rights & Permissions [Opens in a new window]

Abstract

Information

Type
Letter to the Editor
Copyright
© The Author(s), 2026. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America

I wish to thank Dr. Khosrowshahi for his letter Reference Khosrowshahi1 regarding the Society for Healthcare Epidemiology of America (SHEA), Infectious Disease Society of America (IDSA), and Association for Professionals in Infection Control and Epidemiology (APIC) practice recommendations to prevent ventilator-associated pneumonia. Reference Klompas, Branson and Cawcutt2 Dr. Khosrowshahi’s letter expressed concern over the reclassification of subglottic secretion drainage from an Essential Practice to an Additional Approach given that multiple meta-analyses of randomized trials have reported that subglottic secretion drainage is associated with lower VAP rates. Reference Caroff, Li, Muscedere and Klompas3Reference Pozuelo-Carrascosa, Klompas and Alvarez-Bueno5 The reason the panel nonetheless downgraded their recommendation for subglottic secretion drainage was because the balance of evidence suggests that subglottic secretion drainage does not improve patient outcomes.

The panel deemed decreases in VAP rates alone as insufficient evidence to merit an Essential Practice recommendation because of the uncertainty that attends VAP diagnoses. The criteria typically used to define VAP (fever, leukocytosis, increased secretions, new infiltrate, and positive respiratory cultures) are neither sensitive nor specific. Reference Fernando, Tran and Cheng6 As such, perceived decreases in VAP may reflect fewer infections, less colonization, or stricter interpretation of subjective signs (e.g. changes in secretions or radiographic opacities). Reference Klompas7 This a particular concern when trying to evaluate prevention measures that target the same clinical signs that are themselves part of the diagnostic criteria for VAP. Reference Klompas8,Reference Bonten9 Such is the case with subglottic secretion drainage which is designed to reduce respiratory secretions and bioburden. This may lead to fewer positive respiratory cultures and thus fewer patients meeting VAP criteria but it is not clear if this reflects less invasive disease, less colonization, or both. The Practice Recommendations addressed this challenging by restricting Essential Practices to prevention measures with collateral evidence of benefit beyond a decrease in VAP rates alone. Collateral benefits could include a reduction in mortality, duration of mechanical ventilation, ICU or hospital length-of-stay, ventilator-associated events, antibiotic utilization, and/or costs. Reference Klompas, Branson and Cawcutt2 In the case of subglottic secretion drainage, the evidence reviewed by the panel, including the two meta-analyses cited by Dr. Khosrowshahi, found no positive impact on any of these outcomes.

New data published since the release of the SHEA/IDSA/APIC practice recommendations amplify the concern that subglottic secretion drainage may not improve patient outcomes. The PreVent 2 study randomized 1,068 patients requiring endotracheal intubation to either a polyurethane-cuffed endotracheal tube with subglottic secretion drainage or a conventional endotracheal tube without subglottic suction. Reference Treggiari, Sharp and Ohnuma10 The investigators found no significant differences between groups in ventilator-associated events, infection-related ventilator-associated complications, possible VAP, duration of mechanical ventilation, ICU length-of-stay, antibiotic use, antibiotic duration, ICU mortality, in-hospital mortality, 6-month mortality, or 6-month quality of life indicators.

The PreVent 2 trial is the largest and most rigorous evaluation of subglottic drainage to date. It both supports and strengthens the panel’s decision to downgrade subglottic secretion drainage from an Essential Practice to an Additional Approach. Hospitals are advised to preferentially implement other VAP prevention strategies which have been associated with collateral benefits. These include avoiding intubation, minimizing sedation, maintaining and improving physical conditioning, elevating the head of the bed, providing toothbrushing without chlorhexidine, providing early enteral feeding, and changing the ventilator circuit only if visibly soiled or malfunctioning (or per manufacturer’s instructions). Reference Klompas, Branson and Cawcutt2 The balance of evidence suggests these Essential Practices are more likely to improve patient outcomes compared to subglottic secretion drainage.

Financial support

MK declares grant funding from CDC and AHRQ as well as royalties from UpToDate.

No funding was received for the current manuscript.

References

Khosrowshahi, H. Re-evaluate the downgrade of subglottic secretion drainage in VAP prevention guidelines: a call for evidence-based transparency. Infect Control Hosp Epidemiol 2025.10.1017/ice.2025.10346CrossRefGoogle Scholar
Klompas, M, Branson, R, Cawcutt, K, et al. Strategies to prevent ventilator-associated pneumonia, ventilator-associated events, and nonventilator hospital-acquired pneumonia in acute-care hospitals: 2022 Update. Infect Control Hosp Epidemiol 2022;43:687713.10.1017/ice.2022.88CrossRefGoogle ScholarPubMed
Caroff, DA, Li, L, Muscedere, J, Klompas, M. Subglottic secretion drainage and objective outcomes: a systematic review and meta-analysis. Crit Care Med 2016;44:830840.10.1097/CCM.0000000000001414CrossRefGoogle ScholarPubMed
Pozuelo-Carrascosa, DP, Herraiz-Adillo, A, Alvarez-Bueno, C, Anon, JM, Martinez-Vizcaino, V, Cavero-Redondo, I. Subglottic secretion drainage for preventing ventilator-associated pneumonia: an overview of systematic reviews and an updated meta-analysis. Eur Respir Rev 2020;29:190107.10.1183/16000617.0107-2019CrossRefGoogle Scholar
Pozuelo-Carrascosa, DP, Klompas, M, Alvarez-Bueno, C, et al. Correction to subglottic secretion drainage for preventing ventilator-associated pneumonia: an overview of systematic reviews and an updated meta-analysis. Eur Respir Rev 2022;31:220013.10.1183/16000617.0013-2022CrossRefGoogle Scholar
Fernando, SM, Tran, A, Cheng, W, et al. Diagnosis of ventilator-associated pneumonia in critically ill adult patients-a systematic review and meta-analysis. Intensive Care Med 2020;46:11701179.10.1007/s00134-020-06036-zCrossRefGoogle ScholarPubMed
Klompas, M. Eight initiatives that misleadingly lower ventilator-associated pneumonia rates. Am J Infect Control 2012;40:408410.10.1016/j.ajic.2011.07.012CrossRefGoogle ScholarPubMed
Klompas, M. The paradox of ventilator-associated pneumonia prevention measures. Crit Care 2009;13:315.10.1186/cc8036CrossRefGoogle ScholarPubMed
Bonten, MJ. Healthcare epidemiology: ventilator-associated pneumonia: preventing the inevitable. Clin Infect Dis 2011;52:115121.10.1093/cid/ciq075CrossRefGoogle ScholarPubMed
Treggiari, MM, Sharp, ES, Ohnuma, T, et al. Hospital and long-term outcomes for subglottic suction and polyurethane cuff versus standard endotracheal tubes in emergency intubation (PreVent 2): a randomised controlled phase 2 trial. Lancet Respir Med 2026;14:141150.10.1016/S2213-2600(25)00294-2CrossRefGoogle ScholarPubMed